Ikuo Takahashi

Ikuo Takahashi

Auto-generated profile, based on publicly available information

Ikuo Takahashi

Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2008
Verified
Journal Article
Closed access
TKTadashi Koga
Tadashi Koga
ETEriko Tokunaga
Eriko Tokunaga
YSYasushi Sumiyoshi
Yasushi Sumiyoshi
EOEiji Oki
Eiji Oki
SOShinya Oda
Shinya Oda
YMYoshihiko Maehara
Yoshihiko Maehara

10 November 2004
Verified
Journal Article
Closed access
TKTadashi Koga
Tadashi Koga
KSKotaro Shibahara
Kotaro Shibahara
AKAkira Kabashima
Akira Kabashima
YSYasushi Sumiyoshi
Yasushi Sumiyoshi
YKYasue Kimura
Yasue Kimura
YMYoshihiko Maehara
Yoshihiko Maehara


1 April 2006 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
ITIkuo Takahashi
Ikuo Takahashi
YEYasunori Emi
Yasunori Emi
YKYoshihiro Kakeji
Yoshihiro Kakeji
ETEriko Tokunaga
Eriko Tokunaga
SUShin Ushiro
Shin Ushiro
YMYoshihiko Maehara
Yoshihiko Maehara
A phase I study of S-1 and biweekly docetaxel (DOC) combination therapy was conducted to determine the maximum tolerated dose (MTD) and pharmacokinetic parameters. Fourteen patients with advanced or recurrent gastric cancer were analyzed. The treatment consisted of S-1 [body surface area (BSA) <1.25 m2:80 mg/day, 1.25

28 June 2003
Verified
Journal Article
Closed access
ITIkuo Takahashi
Ikuo Takahashi
YMYoshihiko Maehara
Yoshihiko Maehara
TKTadashi Koga
Tadashi Koga
YSYasushi Sumiyoshi
Yasushi Sumiyoshi
TOTatsuo Oshiro
Tatsuo Oshiro
KSKeizo Sugimachi
Keizo Sugimachi

1 January 1996 in Oncology
Verified
Journal Article
Closed access
PDF file
ITIkuo Takahashi
Ikuo Takahashi
YMYoshihiko Maehara
Yoshihiko Maehara
HKHiroki Kusumoto
Hiroki Kusumoto
TKTetsuya Kusumoto
Tetsuya Kusumoto
HBHideo Baba
Hideo Baba
KSKeizo Sugimachi
Keizo Sugimachi
The interaction of cis-1,1-cyclobutanedicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) (NK121) and cis-diammine(glycolato)platinum(II) (254-S), analogues of cis-diamminedichloroplatinum(II) (CDDP), with hyperthermia was examined in vivo. Antitumor activity of the platinum complexes at the maximum tolerated dose (MTD) with or without hyperthermia was evaluated by the tumor growth delay assay using B16F10 melanoma growing in the legs of C57BL/6J mice. MTD of CDDP, NK121 or 254-S at the single intraperitoneal injection with hyperthermia was 8, 50 or 30 mg/kg, respectively. Treatment of the tumor-bearing limb at 43 degrees C for 30 min resulted in a tumor growth delay of 1.1 days. A single dose of CDDP produced a 3.3-day tumor growth delay. When CDDP was injected just before hyperthermia (43 degrees C, 30 min), the growth delay increased to 5.5 days (1.7-fold increase). With NK121, there was a 1.5-day growth delay. In combination with hyperthermia, the tumor growth delay by NK121 was 3.2 days (2.1-fold increase). Injection of 254-S led to a growth delay of 3.5 days, and this delay was extended to 5.7 days (1.6-fold increase) when combined with hyperthermia. Changes in serum blood urea nitrogen (BUN) were determined 5 days after intraperitoneal drug administration with or without hyperthermia. A single administration of CDDP 8 mg/kg resulted in an elevated BUN level, and this was enhanced in combination with hyperthermia (66.3 mg/dl, 2.7-fold over control). NK121 50 mg/kg at 37 degrees C did not result in elevation of BUN, but mild nephrotoxicity was noted in combination with hyperthermia (40.3 mg/dl, 1.6-fold increase over control). The administration of 254-S 30 mg/kg resulted in an elevated BUN level, and this elevation was enhanced in combination with hyperthermia (48.6 mg/dl, 2.0-fold increase over control). Our data showed that NK121 and 254-S as well as CDDP produced greater tumor growth delay together with hyperthermia than did the drug alone. Though these new compounds were designed with reduced nephrotoxicity, attention should be paid to increased nephrotoxicity when combined with hyperthermia.